The FDA has approved an assay to detect specific genetic markers indicating that bacteria are resistant to carbapenem antibiotics, which are widely used in hospitals to treat severe infections.
Methods currently used to identify drug-resistant organisms can take up to 4 days, and additional testing often is needed to confirm that carbapenemase, an enzyme that inactivates carbapenem antibiotics, is present. The Xpert Carba-R Assay can detect and differentiate among the most prevalent genetic markers of carbapenemase in about 48 minutes, according to the manufacturer, Cephid of Sunnyvale, California (http://bit.ly/29qMbGX).
Voelker R. Assay Detects Drug-Resistance Genes. JAMA. 2016;316(7):703. doi:10.1001/jama.2016.10684
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: